Trial · NCT03772340

Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

NCT03772340, Phase 2, Completed, Vanda Pharmaceuticals; results first posted 2025-05-09

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness. Trials, record NCT03772340. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03772340

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
NCT number: NCT03772340
Status: Completed
Phases: Phase 2
Enrollment: 126 participants, actual
Lead sponsor: Vanda Pharmaceuticals
Conditions: Motion Sickness
Interventions: Tradipitant, Placebo
First posted: 2018-12-11
Last updated: 2025-05-09
Results first posted: 2025-05-09

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	The Most Severe Motion Sickness Severity During Vehicle Travel	1 day	As measured by the Motion Sickness Severity Scale (MSSS) (NRS 0-6); Lower score indicates improvement
Primary	Percentage of Vomiting	1 day	Defined as subjects ever vomited (MSSS=6) or terminated early due to severity during the vehicle travel. As measured by the Motion Sickness Severity Scale (NRS 0-6).

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	The Most Severe Motion Sickness Severity During Vehicle Travel	1 day		units on a scale	LEAST_SQUARES_MEAN
PRIMARY	Percentage of Vomiting	1 day		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
The Most Severe Motion Sickness Severity During Vehicle Travel	Tradipitant		3.4	Standard Error 0.238	units on a scale
The Most Severe Motion Sickness Severity During Vehicle Travel	Placebo		3.75	Standard Error 0.239	units on a scale
Percentage of Vomiting	Tradipitant	Vomiting No	52		Participants
Percentage of Vomiting	Placebo	Vomiting No	38		Participants
Percentage of Vomiting	Tradipitant	Vomiting Yes	11		Participants
Percentage of Vomiting	Placebo	Vomiting Yes	25		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Tradipitant	63
Overall Study	STARTED	Placebo	63
Overall Study	COMPLETED	Tradipitant	63
Overall Study	COMPLETED	Placebo	63
Overall Study	NOT COMPLETED	Tradipitant	0
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events8

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Motion Sickness	Ear and labyrinth disorders	Tradipitant	19	63
other	Motion Sickness	Ear and labyrinth disorders	Placebo	27	63
other	Somnolence	Nervous system disorders	Tradipitant	17	63
other	Somnolence	Nervous system disorders	Placebo	8	63
other	Headache	Nervous system disorders	Tradipitant	8	63
other	Headache	Nervous system disorders	Placebo	5	63
other	Nausea	Gastrointestinal disorders	Tradipitant	4	63
other	Nausea	Gastrointestinal disorders	Placebo	2	63

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Tradipitant	0	63
Total, all-cause mortality	Placebo	0	63
Total, other adverse events	Tradipitant	39	63
Total, other adverse events	Placebo	39	63
Total, serious adverse events	Tradipitant	0	63
Total, serious adverse events	Placebo	0	63

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Tradipitant vs Placebo: deaths from any cause	Trial comparisons
Tradipitant vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03772340

GET https://conductscience.org/api/trials/v1/NCT03772340/registered

API reference For AI assistants